Why Great Science Doesn't Sell Itself - Fixing Clinical Research's Commercial Blind Spot

Pavel Trofimov spent roughly 15 years in international B2B sales across complex technical markets before moving into clinical research — where he noticed something the industry treats as normal. Founders, scientists and operational leaders were doing the delivery and the business development themselves. In most other regulated industries, that commercial work sits with a dedicated team. That gap became Lab-2-Business (L2B). Pavel's mission, in his own words: to help excellent scientific and technological companies be as deliberate about winning business as they are about delivering it. In this episode he unpacks the imbalance at the heart of clinical research — delivery machines built to be precise and never make mistakes, with almost no one positioned to make the value clear and turn it into revenue. He's sharp on why founder-led growth hits a ceiling, why he refuses "twin mandates" (so he never becomes the networking "head that changes its body" at every conference), and why he rejects the word "fractional" altogether — he embeds as an extended team member, aligned on scope and outcomes, in it for the long run. The conversation's most provocative turn is on AI-native startups. Pavel argues they face a harder sell than anyone: they're not selling a product into the clinical trial ecosystem, they're selling behaviour change — convincing people to change how they work, measure and invoice. His prediction: once the early adopters move and the regulatory rules settle, the companies that move fastest could own the clinical trial market, and parts of the old industry may simply collapse. Adam and Pavel also trade notes on a live concern: AI "personas" now cold-approaching people on LinkedIn, and why validating that you're talking to a real human matters more than ever. A commercial lens on an industry that rarely applies one to itself. 🎧 LISTEN TO THE AUDIO Spotify: https://open.spotify.com/show/7Ks5oLfSDf0u9F1I8GUjti Apple Podcasts: https://podcasts.apple.com/gb/podcast/adam-walkers-pharma-prescribed-podcast/id1829715970 Amazon Music: https://music.amazon.com/podcasts/1a43eb87-b83e-441d-9a87-321263e3f821/adam-walker%E2%80%99s-pharma-prescribed-podcast Podbean: https://pharmaprescribed.podbean.com Youtube: https://youtu.be/Fb4HYN0J6Zk  Full transcript and episode notes: https://pharmaprescribed.com/episodes ⏱️ CHAPTERS 0:00 Intro 0:35 Meet Pavel and Lab-2-Business 2:00 Spotting the commercial gap 4:00 The limits of founder-led growth 14:00 Embedded, not fractional 18:00 The pivot into life sciences 26:00 AI-native tools and selling behaviour change 35:00 Quickfire and golden rule 👤 ABOUT PAVEL TROFIMOV Founder of Lab-2-Business (L2B). Commercial specialist with ~15 years in international B2B sales across complex technical products and services, now focused on clinical research and life sciences. Works as an embedded commercial team member helping founder-led scientific and technology companies build deliberate, systematic business development — with particular interest in AI-native companies stripping manual work and friction out of clinical trials. 💼 Search "Pavel Trofimov" on LinkedIn 🎙️ ABOUT PHARMA PRESCRIBED Pharma Prescribed is the podcast where leaders, innovators and hidden voices in healthcare open up. No soundbites, no spin. Just raw insight, one prescription at a time. Hosted by biometrics consultant Adam Walker. 🌐 https://pharmaprescribed.com ▶️ https://www.youtube.com/@pharmaprescribedpodcast 💼 https://www.linkedin.com/in/adamwalkerbiometrics 🏢 https://uk.linkedin.com/company/pharma-prescribed-podcast #PavelTrofimov #Lab2Business #ClinicalResearch #BusinessDevelopment #CommercialStrategy #PharmaPrescribed #AIinPharma #ClinicalTrials #FounderLedGrowth #B2BSales #LifeSciences